CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net income (loss)	$ 4,388	$ (36,031)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	3,410	3,199
Stock-based compensation	6,117	6,331
Unrealized foreign currency gains	(311)
Loss on deconsolidation of DOSE		25,685
Loss on extinguishment of debt		186
Change in fair value of stock warrant liability	(43)	1,130
Amortization of debt discount and deferred financing costs		15
Amortization of premium on short-term investments	206
Deferred rent	(1)	61
Change in operating assets and liabilities:
Accounts receivable, net	(4,170)	(1,588)
Inventory	(2,191)	(900)
Prepaid expenses and other current assets	(1,396)	(748)
Accounts payable and accrued liabilities	2,996	1,162
Other assets	26	(120)
Net cash provided by (used in) operating activities	9,031	(1,618)
Investing activities
Proceeds from sale and maturities of short-term investments	41,702
Purchases of short-term investments	(60,724)
Purchase of iDOSE product line and related assets from DOSE Medical		(15,000)
Purchases of property and equipment	(4,236)	(502)
Net cash used in investing activities	(23,258)	(15,502)
Financing activities
Proceeds from public offering, net of issuance costs		113,589
Proceeds from senior secured term and draw-to term loans		6,852
Payments of senior secured term and draw-to term loans		(7,000)
Payments of line of credit		(1,850)
Payments of secured notes	(6,656)	(5,640)
Proceeds from exercise of stock options	3,749	1,719
Share purchases under Employee Stock Purchase Plan	793
Proceeds from exercise of stock warrants	50	428
Net cash (used in) provided by financing activities	(2,064)	108,098
Effect of exchange rate changes on cash and cash equivalents	(293)	57
Net (decrease) increase in cash and cash equivalents	(16,584)	91,035
Cash and cash equivalents at beginning of period	21,572	2,304
Cash and cash equivalents at end of period	4,988	93,339
Supplemental disclosures of cash flow information
Interest paid	253	694
Taxes paid	64	14
Supplemental schedule of noncash investing and financing activities
Reduction of liability upon vesting of stock options previously exercised for unvested stock	$ 54	$ 65